印度钦奈iNDUS骨髓移植小组对2019年美国血液和骨髓移植学会会议要点的总结。
Summary of the Highlights of 2019 ASTCT Meeting by iNDUS BMT Group at Chennai, India.
作者信息
Sharma Ajay, George Biju, Subhash Chezian, Bhurani Dinesh, Choudhary Dharma, Easow Jose, John Joseph, Kumar Lalit, Sidharthan Neeraj, Malhotra Pankaj, Ahmed Rayaz, Raj Revathy, Bhargava Rahul, Yadav Satya Prakash, Damodar Sharat, Nityanand Soniya, Bhat Sunil, Saikia Tapan, Seth Tulika, Nair Velu, Mathews Vikram
机构信息
1Sir Ganga Ram Hospital, New Delhi, India.
2CMC, Vellore, India.
出版信息
Indian J Hematol Blood Transfus. 2019 Jul;35(3):409-415. doi: 10.1007/s12288-019-01152-3. Epub 2019 Jun 21.
Abstract
This article summarises the main highlights of the abstracts presented at the annual meeting of American Society of Transplantation and Cellular Therapy (ASTCT). The highlights of ASTCT meeting were organised by iNDUS BMT group in Chennai, India. The purpose of the highlight meeting was to educate the students about the latest research in the field of hematopoietic stem cell transplantation and its applicability for the developing country perspective.
摘要
本文总结了在美国移植与细胞治疗学会（ASTCT）年会上发表的摘要的主要亮点。ASTCT会议亮点由印度钦奈的iNDUS骨髓移植小组组织。亮点会议的目的是让学生了解造血干细胞移植领域的最新研究及其从发展中国家角度的适用性。
相似文献
1
Summary of the Highlights of 2019 ASTCT Meeting by iNDUS BMT Group at Chennai, India.印度钦奈iNDUS骨髓移植小组对2019年美国血液和骨髓移植学会会议要点的总结。
Indian J Hematol Blood Transfus. 2019 Jul;35(3):409-415. doi: 10.1007/s12288-019-01152-3. Epub 2019 Jun 21.
2
Proceedings of the 2023 Second Annual ASTCT-NMDP ACCESS Initiative Workshop.2023 年第二届 ASTCT-NMDP ACCESS 倡议研讨会会议记录。
Transplant Cell Ther. 2023 Dec;29(12):739-746. doi: 10.1016/j.jtct.2023.09.026. Epub 2023 Oct 5.
3
Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy.造血细胞移植和免疫效应细胞治疗的适应证：美国移植和细胞治疗学会指南。
Biol Blood Marrow Transplant. 2020 Jul;26(7):1247-1256. doi: 10.1016/j.bbmt.2020.03.002. Epub 2020 Mar 9.
4
Proceedings of the 2024 Third Annual ASTCT-NMDP ACCESS Initiative Workshop.2024年第三届ASTCT-NMDP ACCESS倡议年度研讨会会议记录
Transplant Cell Ther. 2024 Dec;30(12):1124-1138. doi: 10.1016/j.jtct.2024.09.004. Epub 2024 Sep 13.
5
Peritransplantation Glucocorticoid Haploidentical Stem Cell Transplantation Is a Promising Strategy for AML Patients With High Leukemic Burden: Comparison With Transplantations Using Other Donor Types.移植前糖皮质激素单倍体相合干细胞移植是高白血病负荷AML患者的一种有前景的策略：与使用其他供体类型的移植比较
Transplant Cell Ther. 2023 Apr;29(4):273.e1-273.e9. doi: 10.1016/j.jtct.2023.01.005. Epub 2023 Jan 12.
6
Updated Indications for Immune Effector Cell Therapy: 2023 Guidelines from the American Society for Transplantation and Cellular Therapy.免疫效应细胞治疗的更新适应症：美国移植与细胞治疗学会2023年指南
Transplant Cell Ther. 2023 Oct;29(10):594-597. doi: 10.1016/j.jtct.2023.07.002. Epub 2023 Jul 6.
7
The ASTCT-NMDP ACCESS Initiative: A Collaboration to Address and Sustain Equal Outcomes for All across the Hematopoietic Cell Transplantation and Cellular Therapy Ecosystem.ASTCT-NMDP ACCESS 倡议：为了在造血细胞移植和细胞治疗生态系统中实现所有参与者的平等结果而进行的合作。
Transplant Cell Ther. 2022 Dec;28(12):802-809. doi: 10.1016/j.jtct.2022.09.020. Epub 2022 Sep 30.
8
Progress toward production of immunologic tolerance with no or minimal toxic immunosuppression for prevention of immunodeficiency and autoimmune diseases.在不使用或仅使用最小毒性免疫抑制的情况下实现免疫耐受以预防免疫缺陷和自身免疫性疾病的进展。
World J Surg. 2000 Jul;24(7):797-810. doi: 10.1007/s002680010128.
9
[Hematopoietic stem cell transplantation for treatment of acute leukemia].造血干细胞移植治疗急性白血病
Gan To Kagaku Ryoho. 1999 Sep;26(10):1387-95.
10
Haploidentical peripheral blood and marrow stem cell transplantation in nine cases of primary immunodeficiency.9例原发性免疫缺陷患者的单倍体相合外周血及骨髓干细胞移植
Haematologica. 2000 Nov;85(11 Suppl):41-6.
引用本文的文献
1
Algorithm to Study HLA-Antibodies and Selecting Criteria for the Best Haploidentical Donor.研究人类白细胞抗原抗体的算法及最佳单倍型相合供体的选择标准
Indian J Hematol Blood Transfus. 2020 Jul;36(3):573-574. doi: 10.1007/s12288-019-01246-y. Epub 2020 Jan 3.
本文引用的文献
1
Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma.多发性骨髓瘤中新型诱导方案与干细胞动员及自体移植微小残留病阴性
Biol Blood Marrow Transplant. 2020 Aug;26(8):1394-1401. doi: 10.1016/j.bbmt.2020.04.011. Epub 2020 May 19.
2
Return-to-Work Guidelines and Programs for Post-Hematopoietic Cell Transplantation Survivors: An Initial Survey.造血干细胞移植后幸存者的重返工作指南与计划：一项初步调查。
Biol Blood Marrow Transplant. 2020 Aug;26(8):1520-1526. doi: 10.1016/j.bbmt.2020.04.022. Epub 2020 Apr 29.
3
Pharmacokinetics and Efficacy of Generic Melphalan Is Comparable to Innovator Formulation in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.在接受自体干细胞移植的多发性骨髓瘤患者中，普通美法仑的药代动力学和疗效与原研药物相当。
Clin Lymphoma Myeloma Leuk. 2020 Feb;20(2):130-135.e1. doi: 10.1016/j.clml.2019.08.013. Epub 2019 Oct 4.
4
Novel Therapies and Approaches to Relapsed/Refractory HL Beyond Chemotherapy.化疗之外针对复发/难治性霍奇金淋巴瘤的新型疗法与方法
Cancers (Basel). 2019 Mar 25;11(3):421. doi: 10.3390/cancers11030421.
5
Host NLRP6 exacerbates graft-versus-host disease independent of gut microbial composition.宿主 NLRP6 加剧移植物抗宿主病，与肠道微生物组成无关。
Nat Microbiol. 2019 May;4(5):800-812. doi: 10.1038/s41564-019-0373-1. Epub 2019 Mar 11.
6
How I treat refractory chronic graft-versus-host disease.我如何治疗难治性慢性移植物抗宿主病。
Blood. 2019 Mar 14;133(11):1191-1200. doi: 10.1182/blood-2018-04-785899. Epub 2019 Jan 23.
7
Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial.老年患者和合并症患者中，高剂量与低剂量清髓性序贯白消安联合氟达拉滨的疗效比较：一项开放标签、非分层、随机2期试验。
Lancet Haematol. 2018 Nov;5(11):e532-e542. doi: 10.1016/S2352-3026(18)30156-X.
8
Graft-versus-host disease.移植物抗宿主病。
Med Clin (Barc). 2019 Jan 4;152(1):22-28. doi: 10.1016/j.medcli.2018.07.012. Epub 2018 Oct 9.
9
Challenges in managing graft-versus-host disease in developing countries: a perspective.发展中国家移植物抗宿主病管理面临的挑战：一种观点。
Bone Marrow Transplant. 2019 May;54(5):641-647. doi: 10.1038/s41409-018-0333-z. Epub 2018 Sep 20.
10
Systemic Sclerosis as an Indication for Autologous Hematopoietic Cell Transplantation: Position Statement from the American Society for Blood and Marrow Transplantation.自身造血干细胞移植治疗系统性硬化症的适应证：美国血液和骨髓移植学会立场声明。
Biol Blood Marrow Transplant. 2018 Oct;24(10):1961-1964. doi: 10.1016/j.bbmt.2018.06.025. Epub 2018 Jun 25.
Zotero 插件